Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Jul 31, 2012

Top Paid Women in Biopharma

GEN’s listing of the 25 highest-paid females in the industry.

Top Paid Women in Biopharma

These 25 women are pulling in the big bucks. [© stefa_neve - Fotolia.com]

  • #25. Paula J. Swain

    EVP, Human resources, Incyte

    2011 Compensation: $1,309,024

  • #24. Patricia S. Andrews

    EVP and Chief Commercial Officer, Incyte

    2011 Compensation: $1,336,538

  • #23. Mary Sontrop

    EVP, Operation, CSL

    2011 Compensation: $1,403,020 (A$1,337,883)

  • #22. B. Lynne Parshall

    Director, COO, CFO, Isis Pharmaceuticals

    2011 Compensation: $1,434,819

  • #21. Marcea Bland Lloyd

    SVP, Chief Administrative Officer and General Counsel, Amylin Pharmaceuticals

    2011 Compensation: $1,615,038

  • #20. Jane Wasman

    Chief, Strategic Development, General Counsel and Corporate secretary, Acorda Therapeutics

    2011 Compensation: $1,645,473

  • #19. Elizabeth B. Rae

    VP, Human Resources, Waters

    2011 Compensation: $1,663,179

  • #18. Tamara Joseph

    SVP, General Counsel and Secretary, Cubist Pharmaceuticals

    2011 Compensation: $2,151,232

  • #17. Deborah L. Tanner

    Corporate EVP and Group President, Research and Development Laboratories, Covance

    2011 Compensation: $2,419,761

  • #16. Jacqualyn A. Fouse

    EVP and CFO, Celgene

    2011 Compensation: $2,535,033

  • #15. Lynn Seely, M.D.

    CMO, Medivation

    2011 Compensation: $2,579,028

  • #14. Martine A. Rothblatt, Ph.D

    Chairman and CEO, United Therapeutics

    2011 Compensation: $3,161,350

  • #13. Helen Torley, M.B., Ch.B

    EVP and CCO, Onyx Pharmaceuticals

    2011 Compensation: $3,346,433

  • #12. Nancy J. Wysenski

    EVP and CCO, Vertex Pharmaceuticals

    2011 Compensation: $3,352,768

  • #11. Cheryl Cohen

    CCO, Medivation

    2011 Compensation: $3,554,519



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »